Table 2.
Baseline | 1-month follow-up | 3-month follow-up | |||||
---|---|---|---|---|---|---|---|
Mean ± SD | p value* | Mean ± SD | p value§ | Mean ± SD | p value§ | p value# | |
BCVA, LogMAR | 0.14 ± 0.09 | 0.232 | 0.135 ± 0.10 | 1.000 | 0.115 ± 0.09 | 0.288 | 0.311 |
IOP, mmHg | 15.5 ± 2.9 | 0.267 | 14.9 ± 2.4 | 0.827 | 14.7 ± 2.4 | 0.300 | 1.000 |
CMT, μm | 275 ± 19 | 0.725 | 276 ± 19 | 1.000 | 273 ± 26 | 1.000 | 1.000 |
Subfoveal ChT, μm | 223 ± 110 | 0.730 | 223 ± 112 | 1.000 | 221 ± 107 | 1.000 | 1.000 |
Retinal thickness (treated area), μm | 295 ± 26 | 0.238 | 294 ± 24 | 1.000 | 292 ± 25 | 0.258 | 0.847 |
ChT (treated area), μm | 197 ± 88 | 0.450 | 195 ± 94 | 1.000 | 201 ± 88 | 1.000 | 0.613 |
ONL thickness (treated area), μm | 59.30 ± 13.50 | 0.001 | 64.75 ± 12.31 | 0.012 | 67.75 ± 15.52 | < 0.001 | 0.213 |
ONL thickness (control area), μm | 51.61 ± 10.91 | 0.199 | 53.39 ± 12.29 | 0.645 | 53.56 ± 12.31 | 0.204 | 1.000 |
MS (macular area), dB | 13.99 ± 4.27 | 0.152 | 13.05 ± 4.19 | 0.148 | 13.65 ± 4.70 | 1.000 | 1.000 |
MS (treated area), dB | 12.08 ± 4.65 | 0.404 | 11.08 ± 5.06 | 0.538 | 11.45 ± 5.70 | 1.000 | 1.000 |
MS (control area), dB | 12.01 ± 4.67 | 0.120 | 11.02 ± 4.45 | 0.112 | 11.69 ± 5.21 | 1.000 | 0.910 |
Fixation percentage (2°), % | 42.5 ± 13.2 | 0.649 | 39.3 ± 15.1 | 1.000 | 40.5 ± 17.3 | 1.000 | 1.000 |
Fixation percentage (4°), % | 83.2 ± 12.8 | 0.342 | 78.3 ± 15.3 | 0.550 | 80.2 ± 11.8 | 0.969 | 1.000 |
SD standard deviation, BCVA best-corrected visual acuity, IOP intraocular pressure, CMT central macular thickness, ChT choroidal thickness, ONL outer nuclear layer, MS retinal sensitivity.
*Analysis of Variance (ANOVA) for paired samples.
§Comparison with baseline using ANOVA for paired samples with Bonferroni post-hoc analysis.
#Comparison with 1-month follow-up using ANOVA for paired samples with Bonferroni post-hoc anaysis.